SIM0270

Phase 3Small molecule

Jiangsu Simcere Pharmaceutical Co., Ltd.

SIM0270 is one of 88 small molecule programs targeting Locally Advanced or Metastatic Breast Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Locally Advanced or Metastatic Breast CancerActive, not recruiting

InteractionRecruiting

Breast CancerActive, not recruiting

Locally Advanced or Metastatic Breast CancerPhase 3

Active, not recruiting

InteractionPhase 1

Recruiting

Breast CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

SIM0270

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 3

1 2

Blenoxane

Bristol-Myers Squibb

Preclinical

1 3

Spravato

WWim Janssens

Preclinical

2 4

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 5

Rilvegostomig

AstraZeneca

Preclinical

1 6

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 7

Neoadjuvant Treatment

SShanghai Zhongshan Hospital

Preclinical

1 8

Tianeptine

Pfizer

Preclinical

1 9

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

1 10

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Interaction

NCT07357610

Q3 2028

Phase 3Active, not recruiting

Locally Advanced or Metastatic Breast Cancer

NCT06680921

Clinical

Trials by Indication[1]

Clinical Trial1 trial

Mass Balance Clinical Trial of SIM0270

Active, not recruiting· Jiangsu Simcere Pharmaceutical Co., Ltd. logo

Jiangsu Simcere Pharmaceutical Co., Ltd.·Phase 1·NCT06654791·6 enrolled

Interaction1 trial

An Open-Label Drug Interaction Clinical Study to Evaluate Itraconazole, Rifampin, Midazolam and SIM0270 in Chinese Healthy Adult Participants

Recruiting· Jiangsu Simcere Pharmaceutical Co., Ltd. logo

Jiangsu Simcere Pharmaceutical Co., Ltd.·Phase 1·NCT07357610·60 enrolled

Tics1 trial

Evaluate the Effects of Food on the Pharmacokinetics of SIM0270

Completed· Jiangsu Simcere Pharmaceutical Co., Ltd. logo

Jiangsu Simcere Pharmaceutical Co., Ltd.·Phase 1·NCT06536036·16 enrolled

Breast Cancer1 trial

Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer

Active, not recruiting· Jiangsu Simcere Pharmaceutical Co., Ltd. logo

Jiangsu Simcere Pharmaceutical Co., Ltd.·Phase 1·NCT05293964·214 enrolled

Locally Advanced or Metastatic Breast Cancer1 trial

A Randomized, Open-label, Phase III Study of SIM0270 Combined With Everolimus Versus Treatment of Physician's Choice in Patients With CDK4/6 Inhibitors Previously Treated , ER+/HER2- Locally Advanced or Metastatic Breast Cancer

Active, not recruiting· Jiangsu Simcere Pharmaceutical Co., Ltd. logo

Jiangsu Simcere Pharmaceutical Co., Ltd.·Phase 3·NCT06680921·482 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for SIM0270. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SIM0270 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SIM0270. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jiangsu Simcere Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Jiangsu Simcere Pharmaceutical Co., Ltd.

SIM0270

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2028

Trials by Indication[1]

Clinical Trial1 trial

Interaction1 trial

Tics1 trial

Breast Cancer1 trial

Locally Advanced or Metastatic Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News